Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

NCT05054725 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: RMC-4630
DRUG: Sotorasib

Sponsor

Revolution Medicines, Inc.

Collaborators

[object Object]
[object Object]